WINS1 Inhibitors
WINS1 inhibitors encompass a diverse array of chemical compounds that exert their effects through the suppression of specific kinases and signaling pathways. For instance, Staurosporine and PD98059 act by restraining the protein kinase C (PKC) and MEK, respectively, both of which are pivotal in the phosphorylation cascades that lead to WINS1 activation. Similarly, LY294002 and Wortmannin are inhibitors of phosphoinositide 3-kinase (PI3K), a key player in the Akt signaling pathway, which is vital for the downstream activation of WINS1. These inhibitors effectively prevent the phosphorylation events necessary for WINS1 activation. Moreover, Lapatinib and Sorafenib serve as tyrosine kinase inhibitors that target receptors such as EGFR and HER2, and kinases like RAF, which are upstream regulators of pathways influencing WINS1 activity. By obstructing these upstream elements, these inhibitors curtail the cascade of signaling events leading to WINS1's functional state.
Further expanding the repertoire of WINS1 inhibitors, U0126, SP600125, and SB203580 specifically target MEK1/2, JNK, and p38 MAPK, respectively. These inhibitors disrupt critical nodes within the MAPK signaling networks that could potentially regulate WINS1's activity. The inhibition of thesekinases dampens the signaling required for WINS1 to become functionally active. Dasatinib and PP2, by inhibiting Src family kinases, act to destabilize the phosphorylation networks that are essential for WINS1's activation. Lastly, Rapamycin's inhibition of mTOR, a key component of the PI3K/Akt pathway, further contributes to the attenuation of WINS1 activation by disrupting downstream signaling. Collectively, these compounds function through a concerted inhibition of specific kinases and signaling pathways to ensure the downregulation of WINS1 activity, thereby serving as direct or indirect inhibitors of WINS1. Each inhibitor, through its unique mechanism of action, contributes to the overall effect of reducing the functional activity of WINS1 without enhancing its expression or activation, thereby providing a multi-faceted approach to the inhibition of this protein.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, including PKC which is involved in signaling pathways relevant to the activation of WINS1. By inhibiting PKC, Staurosporine would impede the phosphorylation events necessary for WINS1 activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of PI3K, a kinase that participates in the Akt signaling pathway. Since PI3K activity is crucial for the activation of downstream targets such as WINS1, LY294002 would prevent its functional activation by blocking PI3K. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which acts upstream of ERK in the MAPK/ERK pathway. As ERK can influence the activity of WINS1, PD98059 would indirectly prevent WINS1 activation by inhibiting ERK phosphorylation and activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that would block the activation of the Akt pathway, thereby inhibiting the phosphorylation and subsequent activation of WINS1. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a tyrosine kinase inhibitor that targets EGFR and HER2, which can be upstream of pathways leading to WINS1 activation. By inhibiting these receptors, Lapatinib would reduce the activation of downstream signaling events that could activate WINS1. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib targets multiple tyrosine kinases including RAF, which is a part of the MAPK/ERK pathway. Inhibition of RAF would decrease ERK activation, thereby indirectly reducing WINS1 functional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, preventing the activation of ERK1/2 in the MAPK pathway. This would attenuate the signaling cascade that could lead to WINS1 activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, a kinase that may be involved in the signaling pathways regulating WINS1 activity. Inhibiting JNK could prevent the activation of transcription factors that modulate WINS1 expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK, which could regulate signaling pathways influencing WINS1 activity. By inhibiting p38 MAPK, SB203580 would indirectly prevent WINS1 activation through these pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor affecting Src family kinases which could be involved in the activation of WINS1. Inhibition of these kinases would impair the phosphorylation cascade necessary for WINS1 activation. | ||||||